OncLiveBiotech Focus Tracking the Oncology PipelineOncLiveIn a second study, researchers sought to accelerate response to ibrutinib by pairing the drug with rituximab in 40 patients with CLL/SLL (median age, 65 years) considered high risk. In all, 38 o…
Pharmacyclics First to Announce Breakthrough Therapy Designation in …Sacramento BeeA Phase II single-arm study of ibrutinib as a monotherapy in patients with MCL who received at least one prior rituximab-containing chemotherapy regimen and who progre…
Pharmacyclics First to Announce Breakthrough Therapy Designation in …The Herald | HeraldOnline.comA Phase II single-arm study of ibrutinib as a monotherapy in patients with MCL who received at least one prior rituximab-containing chemotherapy regimen…
TG Therapeutics, Inc. Opens Expansion Cohorts in Its Phase I/II Trial of TG …PharmaLive (press release) (subscription)Coupled with the clinical activity seen in both rituximab relapsed and refractory patients across the dose levels tested thus far, w…
|
How Safe Is Abbvie’s Dividend?
Seeking Alpha Daclizumab, a next generation biologic, developed with Biogen for multiple sclerosis. Results from the first of two pivotal trials demonstrated strong efficacy in reducing relapse rates and disability performance. The second pivotal trial is fully … |
 Healio |
Inotuzumab/rituximab combination shows promise in NHL
Healio The phase 1/2 study aimed to determine the maximum tolerated dose of inotuzumab ozogamicin plus rituximab (Rituxan, Genentech/Idec Pharmaceuticals) in a cohort of patients with relapsed/refractory CD20+/CD22+ B-cell non-Hodgkin’s lymphoma. |
|
Nanotechnology Against Pollen Allergy
Science Daily (press release) Feb. 11, 2013 — Scientists at the Charité — Universitätsmedizin Berlin have now been able to identify the grass pollen molecule, against which the allergic response of hay fever in children is initiated. In addition, it was shown that the first … |
TG Therapeutics, Inc. Opens Expansion Cohorts in Its Phase I/II Trial of TG …GlobeNewswire (press release)NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (TGTX) today announced that it has amended its Phase I/II study of single agen…
|
Researchers discover how some natural antibodies are able to stop flu
Medical Xpress (Medical Xpress)—Researchers with the Scripps Institute have discovered that three naturally occurring antibodies are able to overcome flu mutations by attaching to a non-changing protein in the flu virus. As they describe in their paper published in … SCRIPPS FINDS WAY TO FIGHT FLU VIRUSU-T San Diego |
|
Multiple Sklerose: Neue Therapiemöglichkeiten und Schwangerschaft
ptext.de (Pressemitteilung) Frank Schmitz, Facharzt für Neurologie und Psychiatrie aus Ladenburg, stellt insbesondere die Fumarsäure (BG 12), Alemtuzumab, Daclizumab, Teriflunomid sowie neue S1P-Modulatoren vor. Da die MS-Diagnose häufig Menschen zwischen dem 20. und … |